Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Go back to Protagonist Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Protagonist Therapeutics (PTGX) Misses Q1 EPS by 3c

May 7, 2020 5:40 PM EDT

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of ($0.72), $0.03 worse than the analyst estimate of ($0.69).

"Based on the highly promising and consistent clinical responses achieved to date, we are pleased to... More